News and Press Releases
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib...
Category: Drug Discovery, Pharmaceutical
Posted: December 18, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Closed Loop Medicine demonstrates application of digital platform for remote blood pressure and medication monitoring
Study published in JMIR validates the feasibility, use and safety of a digital platform for remote, routine monitoring of blood pressure and medication in hypertension patients Findings support the use...
Category: Biotechnology, Other, Pharmaceutical
Posted: December 17, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
17 December 2024 -- New York, US -- Tiziana Life Sciences, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: December 17, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance
Success marked by 18 percent growth in exhibitors and 9 percent in attendees 16 December 2024 – Amsterdam, the Netherlands – CPHI Milan – the world’s largest pharma event – hosted last month...
Category: Pharmaceutical
Posted: December 17, 2024
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics
Brings 2024 Funding Round Total to €24m 16 December 2024 -- Milan, Italy -- BetaGlue Therapeutics S.p.A, an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: December 16, 2024
BetaGlue Therapeutics SpA. Piazzetta Umberto Giordano 4, 20122 Milan, Italy
Exclusive UniSafe® distribution agreement between Owen Mumford and NIPRO exceeds expectations in Japan with new biosimilar launch
13 December 2024 – Oxford, UK – Owen Mumford, a global leader in medical devices, is pleased to announce that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute...
Category: Drug Delivery, Manufacturing and Packing, Pharmaceutical
Posted: December 13, 2024
Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance
Success marked by 18 percent growth in exhibitors and 9 percent in attendees 13 December 2024 – Amsterdam, the Netherlands – CPHI Milan – the world’s largest pharma event –...
Category: Pharmaceutical
Posted: December 13, 2024
Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
12 December 2024 – London, UK, and Palo Alto, CA, US – Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration...
Category: Drug Discovery, Other
Posted: December 12, 2024
Novotech Named a Fierce CRO Award Winner in the Excellence in Clinical Trial Management and Global Operations Categories
11 December 2024 -- Sydney, Australia -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development...
Category: Clinical Trials, Drug Discovery, Logistics, Pharmaceutical
Posted: December 11, 2024
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients Mitsubishi Tanabe Pharma Corporation...
Category: BioManufacturing, Drug Discovery
Posted: December 11, 2024
Dewpoint Therapeutics 451 D Street, Suite 104 Boston, MA 02210 USA
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only...
Category: Other, Pharmaceutical
Posted: December 11, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
PHC Corporation of North America to Unveil LiCellGrow Prototype at Advanced Therapies Week
Innovative Cell Expansion System Enables Real-Time Metabolic Monitoring and Automated Culture Optimization to Accelerate Cell and Gene Therapy Manufacturing 10 December 2024 – Wood Dale, IL, US – PHC Corporation...
Category: BioManufacturing
Posted: December 10, 2024
Accelerating Innovation in Research and Diagnostics with Science-Aware AI
10 December 2024 –Baltimore, MD, US – Sapio Sciences, the science-aware™ lab informatics platform, today announced the highly anticipated speaker lineup and agenda for SapioCon 2025. Taking place from February...
Category: BioManufacturing, Biotechnology, Drug Discovery
Posted: December 10, 2024
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Santhera Receives Positive Recommendation from NICE for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern Ireland Santhera will be working...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
